Table 25Summary of included studies. Comparison 24. Augmenting with mianserin versus continuing with antidepressant (+/− placebo)

StudyPopulationInterventionComparisonDetails of inadequate response/treatment resistanceComments

Ferreri 2001

RCT

France

N=70

Mean age (years): 45.9

Gender (% female): 74

Ethnicity (% BME): NR

Baseline severity: HAMD 27.27 (more severe)

Mianserin 60mg/day + Fluoxetine 20mg/dayFluoxetine 20mg/dayInadequate response to previous fluoxetine treatment after at least 6 weeks of treatment with 20 mg/day

Treatment length (weeks): 6

Outcomes:

  • Depression symptomatology change score
  • Remission
  • Response
  • Discontinuation due to any reason
  • Discontinuation due to side effects

Licht 2002

RCT

Denmark & Iceland

N=197

Mean age (years): 40.0

Gender (% female): 61

Ethnicity (% BME): NR

Baseline severity: NR (unclear severity)

Mianserin 10-30mg/day + Sertraline 100mg/daySertraline 100mg/day + placeboInadequate response (<50% improvement on HAMD) to 6 weeks of open-label treatment with sertraline (50-100mg/day)

Treatment length (weeks): 5

Outcomes:

  • Remission
  • Response
  • Discontinuation due to any reason

BME: black and minority ethnic; HAMD: Hamilton depression scale; NR: not reported; RCT: randomised controlled trial

From: Further-line treatment

Cover of Further-line treatment
Further-line treatment: Depression in adults: Evidence review D.
NICE Guideline, No. 222.
Copyright © NICE 2022.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.